Home » Gilead Sciences Gears Up for Clinical Trials of Inhaled Remdesivir
Gilead Sciences Gears Up for Clinical Trials of Inhaled Remdesivir
Gilead Sciences has gotten approval from the FDA to launch a phase 1 trial of an inhaled version of its antiviral remdesivir for the earlier treatment of COVID-19 patients.
The drugmaker said it plans to start trials in August.
Upcoming Events
-
07May
-
14May
-
30May